Skip to main content
. 2018 Aug 31;9(68):32958–32971. doi: 10.18632/oncotarget.26010

Figure 5. Combined MAP17 and phosphorylation of γH2AX (p-H2AX) analysis of survival in rectal tumors after concurrent chemoradiotherapy.

Figure 5

Overall survival (left) and disease-free survival (right) analysis of the rectal tumor cohort (Supplementary Table 1) used in this study. Cut-off points are the same as those listed above; high MAP17 (0 > 0.75), high pH2AX (> 100).